As the only Japanese and Asian supplier of cosmetic and makeup formulations with production amenities in Europe, Nippon Shikizai has made vital investments in Japan and France to strengthen its competitiveness and better meeting the expectations of its customers. The group, which has nearly doubled in size over the past five years, is investing closely in analysis and growth and mastering state-of-the-art and innovative industrial processes. In the longer term, the Japanese firm additionally wants to invest in facilities in North America.
Whereas the Japanese firm will celebrate next year the 90th anniversary of its foundation in Japan in 1930 and the 20th anniversary of its establishment in France, it has given itself the means to achieve its new ambitions with a sharp increase in its production capabilities in France and Europe.
Over the past five years, the group’s turnover has nearly doubled to reach USD 110 million in 2018 (from USD 63 million in 2014). Export sales, the principle driver of the corporate’s development, have elevated by 44% over three years, especially towards China, which accounts for 34% of the Nippon Shikizai’s turnover.
To fulfill this demand and keep its leadership, Nippon Shikizai has accelerated its investments. Thus, greater than USD 30 million have been earmarked over the 2018/2020 period, principally to extend the majority production capability in the Tsukuba factory, which had already benefited from significant investments between 2014 and 2017, with the construction of a brand new facility for the packaging of makeup merchandise. It ought to be famous that the U.S. authorities accepted this factory for the production of OTC merchandise.
The group additionally recorded robust growth in Europe, the place it has been current in France since 2000 when it acquired Thépenier Pharma & Cosmetics. After an investment of EUR eight million over four years to modernize the production tool and standardize the manufacturing techniques dedicated to “pharma” and cosmetic products, the turnover of Thépenier Pharma & Cosmetics jumped from EUR 9 million in 2014 to EUR 20 million in 2018 and profitability was as much as expectations.